Essilorluxottica (OTC) (ESLOY) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Essilorluxottica is currently conducting a clinical study titled A Monocentre, Randomized, Contralateral Trial to Study the Effect of Temporal Changes in Ocular Biometry of Two Myopia Control Lenses. The study aims to evaluate how two different myopia control lenses affect eye growth in children aged 6 to 13 years over a six-month period. The key objectives are to measure changes in axial length and choroidal thickness, which are critical indicators of myopia progression.
The intervention involves two types of lenslet-based myopia control lenses, named Myopia Control Lens 1 (MCL 1) and Myopia Control Lens 2 (MCL 2). These lenses are designed to slow down eye growth in children, with each participant wearing both types of lenses, one in each eye.
The study is designed as a randomized, parallel, single-masked trial. Participants are randomly assigned to wear either MCL 1 in the right eye and MCL 2 in the left eye, or vice versa. The primary purpose of the study is treatment-focused, aiming to assess the efficacy of these lenses in controlling myopia.
The study began on September 29, 2025, with primary completion expected in six months. The last update was submitted on November 26, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
For investors, the successful development of effective myopia control lenses could significantly impact Essilorluxottica’s market position, potentially boosting stock performance. The study’s outcome could also influence investor sentiment positively, especially in the competitive ophthalmic lens industry.
The study is ongoing, with further details available on the ClinicalTrials portal.